🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07378891
Enrolling by invitation Observational

Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI)

NCT07378891 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2025-12-01
Last updated
2026-02-10

Condition(s) studied

Diabetes (DM)Prediabetes

Study summary

Examination of individuals with prediabetes and established diabetes for early signs of diabetic retinopathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Voluntary adults * Aged between 18 and 80 years * Understanding of the study explanations and instructions * Prediabetes (defined by elevated fasting glucose 100-125 mg/dL and/or 2-hour glucose in the oral glucose tolerance test of 140-199 mg/dL and/or HbA1c of 5.7-6.4%) * manifest diabetes (all types of diabetes according to Ahlqvist) Exclusion Criteria: * participants unable to give consent * Those who do not agree to be informed about incidentally detected pathological findings * Uncontrolled arterial hypertension (Stage III) despite multiple antihypertensive medications * Eye diseases that impair the interpretability of the fundus examination

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Tuebingen, Dep. Diabetology Tübingen Germany

More University Hospital Tuebingen trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07378891 on ClinicalTrials.gov ↗ ← All trials in Germany